The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor assessments according to RECIST versus volumetry: Impact on early changes in tumor size in metastatic colorectal cancer (mCRC).
Ruediger Paul Laubender
Honoraria - Merck KGaA
Research Funding - Merck KGaA
Other Remuneration - Merck KGaA
Ute Sartorius
Employment or Leadership Position - Merck KGaA
Michael Schlichting
Employment or Leadership Position - Merck KGaA
Dominik Paul Modest
Honoraria - Amgen
Other Remuneration - Merck KGaA
Ulrich Robert Mansmann
Research Funding - Merck KGaA
Anno Graser
No relevant relationships to disclose
Volker Heinemann
Consultant or Advisory Role - Merck KGaA; Roche; Sanofi
Honoraria - Merck KGaA; Roche; Sanofi
Research Funding - Merck KGaA
Expert Testimony - Merck KGaA; Roche
Other Remuneration - Merck KGaA; Roche